Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for TScan Therapeutics, Inc. (TCRX : NSDQ)
 
 • Company Description   
TScan Therapeutics Inc. is a biopharmaceutical company. It focused on the development of T-cell receptor engineered T cell therapies for the treatment of patients with cancer. The company's lead product pipeline consist TSC-100 and TSC-101. TScan Therapeutics Inc. is based in WALTHAM, Mass.

Number of Employees: 105

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.05 Daily Weekly Monthly
20 Day Moving Average: 276,280 shares
Shares Outstanding: 23.77 (millions)
Market Capitalization: $72.49 (millions)
Beta:
52 Week High: $14.71
52 Week Low: $1.60
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 24.49% 36.31%
12 Week -27.47% -18.48%
Year To Date -32.22% -17.20%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
830 WINTER STREET
-
WALTHAM,MA 02451
USA
ph: 857-399-9500
fax: -
hsavelle@tscan.com http://www.tscan.com
 
 • General Corporate Information   
Officers
David Southwell - Chief Executive Officer; President and Director
Brian Silver - Chief Financial Officer
Stephen Biggar - Director
Ittai Harel - Director
Timothy Barberich - Director

Peer Information
TScan Therapeutics, Inc. (CORR.)
TScan Therapeutics, Inc. (RSPI)
TScan Therapeutics, Inc. (CGXP)
TScan Therapeutics, Inc. (BGEN)
TScan Therapeutics, Inc. (GTBP)
TScan Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 89854M101
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/18/22
Share - Related Items
Shares Outstanding: 23.77
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $72.49 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.76 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.98 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/18/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.50
Price/Cash Flow: -
Price / Sales: 6.51
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: 49.04%
vs. Previous Quarter: 5.85%
ROE
03/31/22 - -54.09
12/31/21 - -86.48
09/30/21 - -779.91
ROA
03/31/22 - -32.91
12/31/21 - -29.30
09/30/21 - -32.14
Current Ratio
03/31/22 - 7.89
12/31/21 - 7.76
09/30/21 - 8.15
Quick Ratio
03/31/22 - 7.89
12/31/21 - 7.76
09/30/21 - 8.15
Operating Margin
03/31/22 - -510.72
12/31/21 - -479.49
09/30/21 - -522.54
Net Margin
03/31/22 - -510.72
12/31/21 - -479.49
09/30/21 - -522.54
Pre-Tax Margin
03/31/22 - -510.72
12/31/21 - -479.49
09/30/21 - -522.54
Book Value
03/31/22 - 6.13
12/31/21 - 6.76
09/30/21 - 7.33
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©